首页> 美国卫生研究院文献>other >Drug-Target Interaction Prediction via Dual Laplacian Graph Regularized Matrix Completion
【2h】

Drug-Target Interaction Prediction via Dual Laplacian Graph Regularized Matrix Completion

机译:通过双重拉普拉斯图正则化矩阵完成预测药物-靶标相互作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug-target interactions play an important role for biomedical drug discovery and development. However, it is expensive and time-consuming to accomplish this task by experimental determination. Therefore, developing computational techniques for drug-target interaction prediction is urgent and has practical significance. In this work, we propose an effective computational model of dual Laplacian graph regularized matrix completion, referred to as DLGRMC briefly, to infer the unknown drug-target interactions. Specifically, DLGRMC transforms the task of drug-target interaction prediction into a matrix completion problem, in which the potential interactions between drugs and targets can be obtained based on the prediction scores after the matrix completion procedure. In DLGRMC, the drug pairwise chemical structure similarities and the target pairwise genomic sequence similarities are fully exploited to serve the matrix completion by using a dual Laplacian graph regularization term; i.e., drugs with similar chemical structure are more likely to have interactions with similar targets and targets with similar genomic sequence similarity are more likely to have interactions with similar drugs. In addition, during the matrix completion process, an indicator matrix with binary values which indicates the indices of the observed drug-target interactions is deployed to preserve the experimental confirmed interactions. Furthermore, we develop an alternative iterative strategy to solve the constrained matrix completion problem based on Augmented Lagrange Multiplier algorithm. We evaluate DLGRMC on five benchmark datasets and the results show that DLGRMC outperforms several state-of-the-art approaches in terms of 10-fold cross validation based AUPR values and PR curves. In addition, case studies also demonstrate that DLGRMC can successfully predict most of the experimental validated drug-target interactions.
机译:药物-靶标相互作用对于生物医学药物的发现和开发起着重要作用。然而,通过实验确定来完成该任务是昂贵且费时的。因此,开发用于药物-靶标相互作用预测的计算技术是当务之急,具有现实意义。在这项工作中,我们提出了一个有效的双Laplacian图正则化矩阵完成的计算模型,简称为DLGRMC,以推断未知的药物-靶标相互作用。具体而言,DLGRMC将药物-靶标相互作用预测的任务转换为矩阵完成问题,在矩阵完成问题中,可以基于矩阵完成过程后的预测分数获得药物与靶标之间的潜在相互作用。在DLGRMC中,通过使用双重拉普拉斯图正则化项,充分利用了药物对的化学结构相似性和目标对的基因组序列相似性来服务于基质的完成。即,具有相似化学结构的药物更可能与相似靶标发生相互作用,而具有相似基因组序列相似性的靶标更可能与相似药物发生相互作用。此外,在矩阵完成过程中,部署了具有二进制值的指示剂矩阵,该二进制值指示观察到的药物-靶标相互作用的指数,以保存实验确认的相互作用。此外,基于增强拉格朗日乘数算法,我们开发了一种替代的迭代策略来解决约束矩阵完成问题。我们在五个基准数据集上评估了DLGRMC,结果表明,在基于AUPR值和PR曲线的10倍交叉验证方面,DLGRMC优于几种最新方法。此外,案例研究还表明DLGRMC可以成功预测大多数经过实验验证的药物-靶标相互作用。

著录项

  • 期刊名称 other
  • 作者单位
  • 年(卷),期 -1(2018),-1
  • 年度 -1
  • 页码 1425608
  • 总页数 12
  • 原文格式 PDF
  • 正文语种
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号